Abstract：【Objective】 To analyze the relationship between miR-92a and biochemical recurrence after radical prostatectomy.【Methods】 A total of 123 prostate cancer (PCa) patients with radical prostatectomy in urology were enrolled and clinical data of all cases were collected. Meanwhile,the circulation level of miR-92a was detected. After hospital discharged,the biochemical recurrence of patients were followed-up with one year to analyze the correlation between miR-92a and biochemical recurrence. The ROC curve was used to evaluate miR-92a in diagnosis for biochemical recurrence. 【Results】 Compared to the control group,patients with biochemical recurrence had higher level of miR-92a,higher scores PSA and Gleason,and higher rates of lymph node metastasis and tumor differentiation (P<0.05).The miR-92a had a positive correlation with PSA (r=0.527,P=0.036) and Gleason score (r=0.341,P<0.01). The binary6 logistic regression analysis showed that miR-92a was an independent risk factor for biochemical recurrence,whose odds ratio was 2.18 (1.17-5.26).The value of miR-92a was useful in diagnosis of biochemical recurrence:the area under the curve (AUC) (95%CI) was 0.83 (0.75-0.91) and the best diagnostic cut-off was 22.68.Kaplan-Meier survival curve showed the biochemical recurrence-free time of patients with high miR-92a was significantly shorter than that of patients with low miR-92a.【Conclusion】 miR-92a was a potential predictor and independent risk factor for biochemical recurrence after radical prostatectomy.
王媛媛, 许敏. miR-92a与前列腺癌根治术后生化复发的相关性分析[J]. 医学临床研究, 2023, 40(4): 575-577.
WANG Yuan-yuan, XU Min. Relationship of miR-92a with Biochemical Recurrence after Radical Prostatectomy. JOURNAL OF CLINICAL RESEARCH, 2023, 40(4): 575-577.
[1] 瞿元元,戴波. 前列腺癌根治术后生化复发的危险因素[J].现代泌尿外科杂志,2013,12(8):204-206. [2] 叶永康,米其武,罗杰鑫,等. miR-30c在前列腺癌中的临床意义[J].中国现代医学杂志,2015,25(19):36-40. [3] FENG S J,QIAN X S,LI H,et al. Combinations of elevated tissue miRNA-17-92 cluster expression and serum prostate-specific antigen as potential diagnostic biomarkers for prostate cancer [J].Oncol Lett,2017,14(6):6943-6949. [4] 杨盼. miRNA-92a作用EBAG9基因调控前列腺癌增殖机制研究[D].天津:天津医科大学,2016. [5] 李鸣,孙光,贺大林,等. 中国前列腺癌诊断治疗指南[M]. 北京:人民卫生出版社,2011. [6] EDGE S B,BYRD D R,COMPTON C C,et al.AJCC cancer staging manual[M].7th ed. New York:Springer-Verlag,2009:117-126. [7] STEPHENSON A J,KATTAN M W,EASTHAM J A,et al.Defining biochemical recurrence of prostate cancer after radical prostatectomy:a proposal for a standardized definition[J].J Clin Oncol,2006,24(24):3973-3978. [8] 彭扬洋,邱樊,王刚. 血清miRNA-135与PSA联合检测对前列腺癌的诊断价值及与临床特征、预后的关系[J].癌症进展,2020,18(1):69-72. [9] RODRríGUEZ M,BAJO-SANTOS C,HESSVIK N P,et al. Meta-analysis of miRNA expression profiles for prostate cancer recurrence following radical prostatectomy[J].PLoS One,2017,12(6):e0179543. [10] OHAYASHIKI K,UMEZU T,YOSIZAWA S I,et al. Clinical impact of down-regulated plasma miR-92a levels in non-Hodgkin's lymphoma[J].PLoS One,2011,6(2):e16408. [11] TIAN L,FANG Y X,XUE J L,et al.Four microRNAs promote prostate cell proliferation with regulation of PTEN and its down-stream signals in vitro [J].PLoS One,2013,8(9):e75885.
2023, Vol. 40 
